Funder
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,Genetics,Molecular Medicine,General Medicine
Reference160 articles.
1. Barnes TA, Amir E, Templeton AJ, Gomez-Garcia S, Navarro B, Seruga B, et al. Efficacy, safety, tolerability and price of newly approved drugs in solid tumors. Cancer Treat Rev. 2017;56:1–7.
2. Du R, Wang X, Ma L, Larcher LM, Tang H, Zhou H, et al. Adverse reactions of targeted therapy in cancer patients: a retrospective study of hospital medical data in China. BMC Cancer. 2021;21(1):206.
3. Borghaei H, Yim YM, Guerin A, Pivneva I, Shi S, Gandhi M, et al. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy. Lung Cancer. 2018;119:112–9.
4. Grivas P, DerSarkissian M, Shenolikar R, Laliberte F, Doleh Y, Duh MS. Healthcare resource utilization and costs of adverse events among patients with metastatic urothelial cancer in USA. Future Oncol. 2019;15(33):3809–18.
5. Engel-Nitz NM, Johnson MP, Bunner SH, Ryan KJ. Real-world costs of adverse events in first-line treatment of metastatic non-small cell lung cancer. J Manag Care Spec Pharm. 2020;26(6):729–40.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献